Gene Mutations in Non-Small Cell Lung Cancer Cells

Detection of Gene Mutations in Non-small Cell Lung Cancer Cells in Blood Samples or Fine-needle Aspiration

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00977509

Enrollment

200

Registered

2009-09-15

Start date

2009-11-30

Completion date

2014-12-31

Last updated

2013-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carcinoma, Non-Small-Cell Lung

Keywords

genes, mutation, non-small cell lung cancer, cancer cells

Brief summary

To compare the frequency of individual genetic abnormality between tumor cells and blood specimens.

Detailed description

Samples will be collected before the systemic therapy. After initiation of therapy, samples will be collected at end of the 1st month, at the end of the 2nd month at the end of 3rd months and once every three months thereafter concurrently with the tumor assessment such as time of performing CT scans. In selected consented patients, peripheral blood samples will be collected every week for the first month. Disease status will be assessed every 2\ 3 months and at the end of treatment according to RECIST criteria. If progression is not observed at the end of therapy, patients will be assessed every 3 months until progression or further anti-cancer therapy. Progression-free survival, overall survival and response rate will be reported.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Healthy volunteers

Inclusion criteria

* Pathologic or cytological confirmation of NSCLC. * Patients must understand and provide written informed consent prior to initiation of any study-specific procedures. * Have a life expectancy 3 months. * Have malignant pleural/pericardial effusion or metastatic non-small cell lung cancer. * Have measurable or evaluable disease. * ≥20 years. * Candidate for systemic treatment such as EGFR-TKI or chemotherapy.

Exclusion criteria

* Prior history of another malignancy (other than cured basal cell carcinoma of the skin or cured in-situ carcinoma of the cervix) within 5 years of study entry.

Design outcomes

Primary

Measure	Time frame
To determine the frequency of individual genetic abnormality in advanced non-small cell lung cancer (NSCLC) patients who will commence systemic therapy.	Samples will be collected before the systemic therapy, at the end of the first three months and once every 3 months. In selected consented patients, peripheral blood samples will be collected every week for the first month.

Secondary

Measure	Time frame
To determine the frequency with which molecular profiling of a NSCLC patient's tumor by DNA sequencing and/or FISH yields a target against which there is approved or investigational therapeutic regimen.	Samples will be collected before the systemic therapy, at the end of the first three months and once every 3 months. In selected consented patients, peripheral blood samples will be collected every week for the first month.
To determine the response rate according to RECIST, progression-free, and overall survival in patients with advanced NSCLC whose therapy is selected by molecular profile.	Disease status will be assessed every 2~3 months and at the end of treatment according to RECIST criteria. If progression is not observed at the end of therapy, patients will be assessed every 3 months until progression or further anti-cancer therapy.

Countries

Taiwan

Contacts

Primary ContactYa-Ying Bai, M.S.

yaying0508@hotmail.com886-23123456

Outcome results